Reported 11 months ago
In this article, The Motley Fool discusses how some billionaires, including John Overdeck and Ken Griffin, have recently invested in Pfizer and Merck. Despite Pfizer's recent struggles, its success in the COVID-19 market and expanding pipeline make it a favorable long-term investment. Merck, known for Keytruda, continues to grow in the oncology market with new promising products and acquisitions. Both companies have a history of increasing dividends and are considered attractive for income-seeking long-term investors.
Source: YAHOO